Background Excess weight gain has been reported in some adults on dolutegravir (DTG), but data in children/adolescents living with human immunodeficiency virus (CALHIV) are limited. Methods CALHIV aged 2-17 years at DTG start from 15 observational cohorts across Europe and Thailand were included. Mixed models described changes in body-mass-index-for-age z-score (zBMI). We assessed (1) zBMI change 48 weeks before versus after DTG start; (2) zBMI change up to 96 weeks on DTG and associated factors; and (3) zBMI changes over 96 weeks in CALHIV aged 6-17 years at start of DTG versus protease inhibitor (PI)-based regimens using propensity score weighting. Results Of 948 CALHIV on DTG (>99% HIV-1, <1% HIV-2), 50% were female, the median age was 13.7 (interquartile range [IQR], 11.1-15.6]) years, median zBMI was 0.31 (IQR, -0.64 to 1.19), 48% were Black, and 30% were overweight or obese at DTG start. Among 741 participants with zBMI available before and after DTG start, zBMI (95% confidence interval (CI) increased by 0.07 (.03-.11) versus 0.13 (.09-.16) (P =. 087), in the 48 weeks before and after DTG start, respectively. Mean zBMI change by 96 weeks on DTG was 0.20 (95% CI. 14-.27). In multivariable models, greatest increases in zBMI were in those aged 6-11 years at DTG start (0.34 [95% CI. 23-.44]), males of "other"ethnicity (0.39 [95% CI. 10-.68]), Black females (0.27 [95% CI. 15-.39]), and those on tenofovir alafenamide (TAF) (0.39 [95% CI. 17-.61]). There was no difference in mean zBMI change at 96 weeks among those on DTG- versus PI-based regimens (0.21 [95% CI. 13-.30] vs 0.30 [95% CI. 13-.48]; P =. 354). Conclusions CALHIV experienced zBMI increases on DTG with the largest gains in children aged 6-11 years, on TAF, with low baseline zBMI, and some variation by sex and ethnicity. However, zBMI changes over 96 weeks were comparable between those on DTG- and PI-based regimens.
Changes in Body Mass Index in Children and Adolescents Living with Human Immunodeficiency Virus in Europe and Thailand Starting Dolutegravir / Chappell E.; Crichton S.; Collins I.J.; Valle G.D.; Duff C.; Edgar K.; Giaquinto C.; Jackson C.; Judd A.; Mangiarini L.; O'Rourke J.; Scott K.; Thorne C.; Goetghebuer T.; Hainaut M.; Tremerie W.; Delforge M.; Hoffmann T.U.; Nordly S.B.; Braun M.B.; Spoulou V.; Galli L.; Chiappini E.; Lisi C.; Montagnani C.; Venturini E.; Marczynska M.; Popielska J.; Pokorska-Spiewak M.; Oldakowska A.; Zawadka K.; Pluta M.; Doroba M.; Ene L.; Mellado M.J.; Escosa L.; Hortelano M.G.-L.; Sainz T.; Grasa C.; Rodriguez P.; Ramos J.T.; Rojo P.; Prieto-Tato L.; Epalza C.; Tagarro A.; Dominguez S.; Ballesteros A.; Illan M.; Berzosa A.; Guillen S.; Soto B.; Navarro M.L.; Saavedra J.; Santos M.; Rincon E.; Aguilera D.; Santiago B.; Martin B.L.; Suarez A.L.; Bermejo A.; Penin M.; Martinez J.; Badillo K.; Jimenez A.B.; Navas A.; Onate E.; Pocheville I.; Garrote E.; Colino E.; Afonso O.; Sirvent J.G.; Garzon M.; Roman V.; Angulo R.; Neth O.; Falcon L.; Terol P.; Santos J.L.; Vazquez A.; Carazo B.; Medina A.; Lendinez F.; Ibanez M.; Peromingo E.; Sanchez M.I.; Ruiz B.; Grande A.; Romero F.J.; Perez C.; Mendez A.; Calle-Miguel L.; Del Rio V.C.; Pareja M.; Losada B.; Herranz M.; Bustillo M.; Collado P.; Couceiro J.A.; Vila L.; Calvino C.; Piqueras A.I.; Oltra M.; Gavilan C.; Montesinos E.; Dapena M.; Jimenez B.; Andres A.G.; Marugan V.; Ochoa C.; Menasalvas A.I.; Cervantes E.; Diez C.; Bernardino I.; Montes M.L.; Valencia E.; Delgado A.; Rubio R.; Pulido F.; Bisbal O.; Alonso A.M.; Berenguer J.; Aldamiz T.; Tejerina F.; De Quiros J.C.B.; Padilla B.; Carrillo R.; Montilla P.; Bermudez E.; Valerio M.; Sanz J.; Gimeno A.; Cervero M.; Torres R.; Moreno S.; Perez M.J.; Del Campo S.; Ryan P.; Troya J.; Sanz J.; Losa J.; Gomez R.; Gorgolas M.; Diaz A.; De La Fuente S.; Iribarren J.A.; Jose Aramburu M.; Martinez L.; Goikoetxea A.J.; Ibarra S.; De La Pena M.; Asensi V.; Hernandez M.; Aleman M.R.; Pelazas R.; Del Mar Alonso M.; Lopez A.M.; Garcia D.; Rodriguez J.; Cardenes M.A.; Castano M.A.; Orihuela F.; Perez I.; Mayorga M.I.; Lopez-Cortes L.F.; Roca C.; Llaves S.; Jose Rios M.; Rodriguez J.; Palomo V.; Pasquau J.; Garcia C.; Hernandez J.; Martinez C.; Rivero A.; Camacho A.; Merino D.; Raffo M.; Corpa L.; Martinez E.; Mateos F.; Blanch J.J.; Torralba M.; Arazo P.; Samperiz G.; Miralles C.; Ocampo A.; Pousada G.; Mena A.; Montero M.; Salavert M.; Jose Galindo M.; Pretel N.; Portilla J.; Portilla I.; Gutierrez F.; Masia M.; Robledano C.; Adsuar A.; Hinojosa C.; Monteagudo B.; Bachiller P.; Abadia J.; Galera C.; Albendin H.; Fernandez M.; Blanco J.R.; Soler-Palacin P.; Frick M.A.; Perez-Hoyos S.; Lopez N.; Mendez M.; Carreras C.; Guarch-Ibanez B.; Vallmanya T.; Minguell-Domingo L.; Calavia O.; Garcia L.; Coll M.; Pineda V.; Rius N.; Rovira N.; Duenas J.; Fortuny C.; Gamell A.; Noguera-Julian A.; Naver L.; Einarsson N.; Hagas V.; Rubin J.; Soeria-Atmadja S.; Abela I.A.; Aebi-Popp K.; Anagnostopoulos A.; Battegay M.; Baumann M.; Bernasconi E.; Braun D.L.; Bucher H.C.; Calmy A.; Cavassini M.; Ciuffi A.; Crisinel P.-A.; Darling K.E.A.; Dollenmaier G.; Duppenthaler A.; Egger M.; Elzi L.; Fehr J.S.; Fellay J.; Francini K.; Furrer H.; Fux C.A.; Gunthard H.F.; Hachfeld A.; Haerry D.H.-U.; Hasse B.; Hirsch H.H.; Hoffmann M.; Hosli I.; Huber M.; Jackson-Perry D.; Kahlert C.R.; Keiser O.; Klimkait T.; Kohns M.; Kottanattu L.; Kouyos R.D.; Kovari H.; Kusejko K.; Labhardt N.D.; Leuzinger K.; De Tejada B.M.; Marzolini C.; Metzner K.J.; Muller N.; Nemeth J.; Nicca D.; Notter J.; Paioni P.; Pantaleo G.; Perreau M.; Polli C.; Ranieri E.; Rauch A.; Salazar-Vizcaya L.P.; Schmid P.; Segeral O.; Speck R.F.; Stockle M.; Tarr P.E.; Than L.M.; Trkola A.; Wagner N.; Wandeler G.; Weisser M.; Yerly S.; Nadsasarn R.; Saisaengjan C.; Deeklum P.; Khamkhen P.; Pitikawinwong L.; Tantawarak N.; Kosalaraksa P.; Kakkaew C.; Kaleeva T.; Baryshnikova Y.; Raus I.; Glutshenko O.; Sherstiuk H.; Shkurka I.; Delikhovska N.; Popova I.; Golubieva T.; Volokha A.; Malyuta R.. - In: OPEN FORUM INFECTIOUS DISEASES. - ISSN 2328-8957. - ELETTRONICO. - 12:(2025), pp. ofaf640.0-ofaf640.0. [10.1093/ofid/ofaf640]
Changes in Body Mass Index in Children and Adolescents Living with Human Immunodeficiency Virus in Europe and Thailand Starting Dolutegravir
Galli L.;Chiappini E.;
2025
Abstract
Background Excess weight gain has been reported in some adults on dolutegravir (DTG), but data in children/adolescents living with human immunodeficiency virus (CALHIV) are limited. Methods CALHIV aged 2-17 years at DTG start from 15 observational cohorts across Europe and Thailand were included. Mixed models described changes in body-mass-index-for-age z-score (zBMI). We assessed (1) zBMI change 48 weeks before versus after DTG start; (2) zBMI change up to 96 weeks on DTG and associated factors; and (3) zBMI changes over 96 weeks in CALHIV aged 6-17 years at start of DTG versus protease inhibitor (PI)-based regimens using propensity score weighting. Results Of 948 CALHIV on DTG (>99% HIV-1, <1% HIV-2), 50% were female, the median age was 13.7 (interquartile range [IQR], 11.1-15.6]) years, median zBMI was 0.31 (IQR, -0.64 to 1.19), 48% were Black, and 30% were overweight or obese at DTG start. Among 741 participants with zBMI available before and after DTG start, zBMI (95% confidence interval (CI) increased by 0.07 (.03-.11) versus 0.13 (.09-.16) (P =. 087), in the 48 weeks before and after DTG start, respectively. Mean zBMI change by 96 weeks on DTG was 0.20 (95% CI. 14-.27). In multivariable models, greatest increases in zBMI were in those aged 6-11 years at DTG start (0.34 [95% CI. 23-.44]), males of "other"ethnicity (0.39 [95% CI. 10-.68]), Black females (0.27 [95% CI. 15-.39]), and those on tenofovir alafenamide (TAF) (0.39 [95% CI. 17-.61]). There was no difference in mean zBMI change at 96 weeks among those on DTG- versus PI-based regimens (0.21 [95% CI. 13-.30] vs 0.30 [95% CI. 13-.48]; P =. 354). Conclusions CALHIV experienced zBMI increases on DTG with the largest gains in children aged 6-11 years, on TAF, with low baseline zBMI, and some variation by sex and ethnicity. However, zBMI changes over 96 weeks were comparable between those on DTG- and PI-based regimens.I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.



